Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side effects
Merck’s patent on Keytruda is set to expire in 2028. Image: Brendan McDermid (Reuters) Merck announced Monday that it is pulling the plug on its phase 3 trial of an experimental combination treatment for skin cancer after side effects of the medication led …